

BILL SUMMARY
1st Session of the 59th Legislature

Bill No.:	SB665
Version:	ENGR
Request Number:	
Author:	Rep. Worthen
Date:	4/5/2023
Impact:	\$0

Research Analysis

The engrossed version of SB 665 removes the requirement for providers of buprenorphine with naloxone, as used for medication-assisted treatment services, to register with the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control.

Prepared By: Matthew Brenchley

Fiscal Analysis

This measure clarifies language relating to when public or private medical facilities must obtain a certain registration from the Oklahoma Bureau of Narcotics and Dangerous Drugs. In its current form, SB665 is not anticipated to have an impact on state budget or appropriations.

Prepared By: Robert Flipping IV, House Fiscal Staff

Other Considerations

None.